Abstract 307P
Background
Lacrimal gland is an exocrine secretory gland located at the upper temporal fossa of the orbit. It is part of the tear-forming apparatus that constitutes an important orbital structure. However, data available about tumors possibly originating in this site are scarce. In this study, we aimed to spotlight on this rare type of malignancy using the using data from American National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program.
Methods
We used SEER*Stat version 8.3.4, Microsoft Excel, as well as SPSS IBM SPSS Statistics for Windows, Version 21.0. In SEER*Stat, we used the (Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2015 Sub (1973-2013 varying)) database. We included SEER 18 cases that were diagnosed after 2003 (2004+) in which the primary site was identified as (C69.5 – Lacrimal gland). Only cases with malignant behavior, known age, and those in the Research Database were included.
Results
A total of 491 cases were identified with a median age of 63. Females represented the majority of the analyzed cohort (n = 263, 53.6%). Lacrimal gland tumors were most common among the white race (n = 376, 76.6%). Age-adjusted Incidence rate was 0.6 per 1,000,000 with a median survival of 41 months, while 5-year relative survival was 88.4% (CI: 81.9% - 92.6%). The most common pathology of studied cases was Non-Hodgkin lymphoma (n = 254, 51.7%) (Table).Table:
307P Different pathological subtypes for lacrimal gland tumours
Pathological Subtype | N. | % |
---|---|---|
NHL-Mature B-Cell Lymphomas | 254 | 51.7 % |
Squamous Cell Neoplasms | 71 | 14.5 % |
Adenomas &Adenocarcinomas | 64 | 13.0 % |
Malignant Lymphomas, NOS Or Diffuse | 32 | 6.5 % |
Mucoepidermoid Neoplasms | 17 | 3.5 % |
Epithelial Neoplasms, NOS | 10 | 2.0 % |
Nevi Melanomas | 8 | 1.6 % |
Ductal & Lobular Neoplasms | 7 | 1.4 % |
Lymphoid Leukemias (C42.1) | 6 | 1.2 % |
Transitional Cell Papillomas & Carcinomas | 4 | 0.8 % |
Complex Mixed & Stromal Neoplasms | 4 | 0.8 % |
Myomatous Neoplasms | 3 | 0.6 % |
Basal Cell Neoplasms | 2 | 0.4 % |
Complex Epithelial Neoplasms | 2 | 0.4 % |
Plasma Cell Tumors | 2 | 0.4 % |
Unspecified Neoplasms | 1 | 0.2 % |
Cystic, Mucinous & Serous Neoplasms | 1 | 0.2 % |
Fibromatous Neoplasms | 1 | 0.2 % |
Hodgkin Lymphomas | 1 | 0.2 % |
Nhl-Mature T & Nk-Cell Lymphomas | 1 | 0.2 % |
Conclusions
Lacrimal gland tumors are extremely rare with incidence rate of 0.6 per million. These tumors are more likely to occur in old age, females, white race. 5-years relative survival is 88.4% with a median survival of 41 months.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
9P - XRCC1 Arg194Trp, Palb2 T1100T (3300T>G), HMMR V353A, TNF aG308A polymorphisms as diagnostic and prognostic markers of breast cancer in the Kyrgyz ethnic group
Presenter: Aigul Semetei kyzy
Session: Poster display session
Resources:
Abstract
232P - Early Results from the Phase I Study of SY-1365, a Potent and Selective CDK7 inhibitor, in Patients with Ovarian Cancer and Advanced Solid Tumors
Presenter: Debra Richardson
Session: Poster display session
Resources:
Abstract
382P - Drug metabolizing enzymes pharmacogenomic: Biomarkers for improved chemotherapy in head and neck cancer squamous cell carcinoma
Presenter: Sunishtha Bhatia
Session: Poster display session
Resources:
Abstract
401P - Women in oncology: Alarming figures from India
Presenter: Sharada Mailankody
Session: Poster display session
Resources:
Abstract
416P - Multidisciplinary management of sarcomas of the head and neck: An institutional experience
Presenter: Kavitha Jain
Session: Poster display session
Resources:
Abstract
523P - Co-morbilities and survival of patients initially diagnosed with extensive-stage small cell lung cancer: Impact of hypertension, diabetes and chronic hepatitis B viral infection
Presenter: Weigang Xiu
Session: Poster display session
Resources:
Abstract
529P - Osimertinib for patients with EGFR-mutant advanced NSCLC and asymptomatic brain metastases: An open-label, two-arm, phase II study
Presenter: Roni Gillis
Session: Poster display session
Resources:
Abstract